<DOC>
	<DOC>NCT01830127</DOC>
	<brief_summary>To assess the pharmacokenetic characteristics of 600 mg BID BI 207127 / 120 mg QD faldaprevir /ribavirin in a small number of GT1b HCV infected patients with mild hepatic impairment (CPA) (Arm 1) versus 400 mg BID BI 207127 / 120 mg QD faldaprevir /ribavirin in a small number of GT1b HCV infected patients with moderate hepatic impairment (CPB) (Arm 2).</brief_summary>
	<brief_title>BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Inclusion criteria: 1. Treatment na√Øve and treatment experienced patients (prior relapse, interferon intolerant, and [allowed in Cohort A only] prior partial response). 2. Chronic HCV infection of genotype 1 (GT1), subGT1b virus only. 3. Liver cirrhosis defined as Metavir Grade=4 or Ishak Grade =5 on liver biopsy or liver stiffness of =13 kPa on fibroscan. Exclusion criteria: 1. HCV infection of mixed genotype (1/2, 1/3, and 1/4) or mixed subGT1a/1b or undefined diagnosed by genotypic testing at screening 2. Liver disease due to causes other than chronic HCV infection which may include but is not limited to hemochromatosis, Wilson's disease, or autoimmune liver diseases. 3. HIV infection 4. Patients who have been previously treated with an investigational or approved DAA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>